Form 4: ResMed Director Peter C. Farrell Sells 2,000 Shares Under 10b5-1 Plan

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $242.11 per share on February 5, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 5, 2025, Peter C. Farrell, a director of ResMed Inc., sold 2,000 shares of ResMed common stock.
• The sale was executed at a price of $242.11 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on May 28, 2024.
• Following the transaction, Farrell directly owns 77,218 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 plan and doesn't necessarily reflect a change in the director's outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of overall company performance and insider sentiment. A pre-planned sale under a 10b5-1 plan is generally viewed as less indicative of insider sentiment than discretionary sales.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the fact that it was pre-planned under a 10b5-1 plan mitigates potential concerns.

Key Dates

Keywords

ResMed, Peter C. Farrell, Form 4, share sale, 10b5-1 plan, director, RMD, securities